BCL-2 inhibition: stemming the tide of myeloid malignancies.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 23472867.
- Also identified by DOI 10.1016/j.stem.2013.02.006 and PMC identifier 3705714.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Leukemia stem cells (LSCs) are likely to be the source for both therapeutic resistance and relapse in myeloid malignancies. As reported in this issue of Cell Stem Cell, Lagadinou et al. (2013) and Goff et al. (2013) support selective targeting of LSCs by small molecule antagonists of anti-apoptotic BCL-2 family proteins.
Medical subject headings
- Leukemia
- Leukemia, Myeloid, Acute
- Neoplastic Stem Cells
- Protein Kinase Inhibitors
- Proto-Oncogene Proteins c-bcl-2